Part 2: Immune Thrombocytopenia
Thomas G. DeLoughery, MD, FACP
Professor of Medicine, Pathology, and Pediatrics, Division of Hematology/Medical Oncology, Knight Cancer Center, Departments of Medicine and Pediatrics, and Division of Laboratory Medicine, Department of Pathology, Oregon Health Sciences University, Portland, OR
A 45-year-old man with ITP who has been undergoing treatment for the condition for several years without success presents to discuss his options. He was treated with steroids with 3 “bursts and tapers” of prednisone but relapsed. He underwent splenectomy but soon relapsed. He then was treated with rituximab but did not respond. He is interested in thrombopoietin mimetic therapy but does not want to come to clinic weekly for injections. The physician discusses eltrombopag with him. What is a unique side effect of eltrombopag that must be monitored and that the patient must be informed about?